Resumen
Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 647-651 |
Número de páginas | 5 |
Publicación | Cell Stem Cell |
Volumen | 13 |
N.º | 6 |
DOI |
|
Estado | Published - dic. 5 2013 |
Publicado de forma externa | Sí |
Nota bibliográfica
Funding Information:The research for this article was conducted as part of the “Asian Biopoleis: Biotechnology and Biomedicine as emergent Forms of Life and Practice” Project, funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS).
ASJC Scopus Subject Areas
- Molecular Medicine
- Genetics
- Cell Biology